BR0314471A - Detecção, localização e estadiamento de tumores usando linfócitos ativados classificados dirigidos a um epitopo especìfico do tumor - Google Patents

Detecção, localização e estadiamento de tumores usando linfócitos ativados classificados dirigidos a um epitopo especìfico do tumor

Info

Publication number
BR0314471A
BR0314471A BR0314471-2A BR0314471A BR0314471A BR 0314471 A BR0314471 A BR 0314471A BR 0314471 A BR0314471 A BR 0314471A BR 0314471 A BR0314471 A BR 0314471A
Authority
BR
Brazil
Prior art keywords
antigen
specific
cells
lymphocytes
cell
Prior art date
Application number
BR0314471-2A
Other languages
English (en)
Inventor
Catherine A Phillips
Stephen E Wright
Original Assignee
Us Dept Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Dept Veterans Affairs filed Critical Us Dept Veterans Affairs
Publication of BR0314471A publication Critical patent/BR0314471A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"DETECçãO, LOCALIZAçãO E ESTADIAMENTO DE TUMORES USANDO LINFóCITOS ATIVADOS CLASSIFICADOS DIRIGIDOS A UM EPITOPO ESPECìFICO DO TUMOR". São divulgados métodos para detectar e localizar um antígeno específico da célula em um mamífero, como um ser humano, que consiste na exposição de células mononucleares de sangue periférico (PBMCs) do mamífero a um epitopo de peptídeo imunogênico do antígeno, sob condições para a ativação de linfócitos T específicos do antígeno nas PBMCs, produzindo linfócitos T específicos do antígeno que possam pelo menos se ligar ao antígeno específico da célula. Os linfócitos T etiquetados (classificados) específicos do antígeno são administrados ao mamífero, normalmente sem IL-2, de forma intraperitoneal ou intravenosa. A distribuição dessas células no mamífero é determinada por imagem, detectando e localizando antígeno específico da célula no mamífero. A exposição de PBMCs ao peptídeo imunogênico normalmente envolve uma preparação de peptídeo livre de célula e interleucina-2 (IL), mas nenhuma célula adicional como células apresentadoras de antígeno (APC) pulsadas com antígeno. Os linfócitos T específicos de antígeno normalmente são citolíticos para células que expressam o antígeno específico da célula e podem consistir em células T CD4+, CD8+ e/ou de memória CD45RO+.
BR0314471-2A 2002-10-10 2003-10-10 Detecção, localização e estadiamento de tumores usando linfócitos ativados classificados dirigidos a um epitopo especìfico do tumor BR0314471A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41730302P 2002-10-10 2002-10-10
PCT/US2003/032602 WO2004033667A2 (en) 2002-10-10 2003-10-10 Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope

Publications (1)

Publication Number Publication Date
BR0314471A true BR0314471A (pt) 2005-08-02

Family

ID=32093998

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314471-2A BR0314471A (pt) 2002-10-10 2003-10-10 Detecção, localização e estadiamento de tumores usando linfócitos ativados classificados dirigidos a um epitopo especìfico do tumor

Country Status (11)

Country Link
US (1) US20060171883A1 (pt)
EP (1) EP1554575A2 (pt)
JP (1) JP2006505554A (pt)
KR (1) KR20050062605A (pt)
CN (1) CN1711475A (pt)
AU (1) AU2003287091B2 (pt)
BR (1) BR0314471A (pt)
CA (1) CA2501527A1 (pt)
EA (1) EA200500625A1 (pt)
MX (1) MXPA05003843A (pt)
WO (1) WO2004033667A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100579577C (zh) 2002-03-15 2010-01-13 退伍军人事务研发服务部 使用细胞脱唾液酸决定簇和糖缀合物将细胞靶向组织和器官的方法和组合物
US20110082091A1 (en) * 2009-09-28 2011-04-07 Theramab Gmbh Method for Preclinical Testing of Immunomodulatory Drugs
WO2016105536A2 (en) * 2014-12-23 2016-06-30 University Of Maryland, Baltimore Muc1 decoy peptides for treatment and prevention of bacterial infections
US11300695B2 (en) 2020-04-24 2022-04-12 Ronald Nutt Time-resolved positron emission tomography encoder system for producing event-by-event, real-time, high resolution, three-dimensional positron emission tomographic image without the necessity of performing image reconstruction
US11054534B1 (en) 2020-04-24 2021-07-06 Ronald Nutt Time-resolved positron emission tomography encoder system for producing real-time, high resolution, three dimensional positron emission tomographic image without the necessity of performing image reconstruction

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4466951A (en) * 1982-11-12 1984-08-21 University Of California Intracellular trapping of therapeutics or tracer agents
EP0214969A4 (en) * 1984-04-19 1987-12-17 Univ Queensland CONTRACEPTIVE METHODS AND DISTRIBUTION SYSTEMS THEREFOR.
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5284646A (en) * 1986-07-03 1994-02-08 Advanced Magnetics Inc. Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents
US5342607A (en) * 1986-07-03 1994-08-30 Advanced Magnetics, Inc. Receptor mediated endocytosis type magnetic resonance imaging contrast agents
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US5262176A (en) * 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5352432A (en) * 1986-07-03 1994-10-04 Advanced Magnetics, Inc. Hepatocyte specific composition and their use as diagnostic imaging agents
US5679323A (en) * 1986-07-03 1997-10-21 Advanced Magnetics, Inc. Hepatocyte-specific receptor-mediated endocytosis-type compositions
DK172391B1 (da) * 1986-12-30 1998-05-18 Nihon Mediphysics Co Ltd Højmolekylær forbindelse til anvendelse som ikke-radioaktiv bærer, radioaktivt mærket højmolekylær forbindelse, fremgangsmåde til fremstilling deraf og fremgangsmåde til forbedret mærkning af en asialoglycoproteinacceptor-dirigerende forbindelse
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5270199A (en) * 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US5043260A (en) * 1987-11-02 1991-08-27 Rhode Island Hospital Perfusion device with hepatocytes
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
ZA922265B (en) * 1991-03-28 1992-12-30 American Cyanamid Co Somatostatin receptor
US5352670A (en) * 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
KR950014915B1 (ko) * 1991-06-19 1995-12-18 주식회사녹십자 탈시알로당단백-포함화합물
US5254342A (en) * 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5814295A (en) * 1992-04-10 1998-09-29 The Ohio State University Research Foundation Determination of lymph nodes enriched in tumor reactive cells their proliferation and their use in adoptive cellular therapy
US5616690A (en) * 1992-06-09 1997-04-01 Neorx Corporation Hexose derivatized human serum albumin clearing agents
US5624896A (en) * 1992-06-09 1997-04-29 Neorx Corporation Clearing agents useful in pretargeting methods
ATE210464T1 (de) * 1992-06-09 2001-12-15 Neorx Corp BIOTIN-DOTA KONJUGATE UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
US5322682A (en) * 1992-08-06 1994-06-21 The Regents Of The University Of California Method for quantitatively measuring and mapping stored iron in tissue using MRI
US5656609A (en) * 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
WO1994018562A1 (en) * 1993-02-05 1994-08-18 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
US5527884A (en) * 1993-12-21 1996-06-18 President And Fellows Of Harvard College Mediators of chronic allograft rejection and DNA molecules encoding them
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
US5840859A (en) * 1995-07-06 1998-11-24 Research Corporation Technologies, Inc. (Aminostyryl)pyridinium compounds for radiolabelling cell membranes
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5683866A (en) * 1996-05-09 1997-11-04 Sarkar; Debi P. Process for producing a targeted gene
US6146614A (en) * 1996-07-02 2000-11-14 Massachusetts Institute Of Technology Method for determining lymphocyte distribution and trafficking in mammals using imaging
US5719020A (en) * 1996-09-25 1998-02-17 Oklahoma Medical Research Foundation 4,7-dialkoxy N-acetylneuraminic acid derivatives and methods for detection of influenza type A and B viruses in clinical specimens
WO1998050527A1 (en) * 1997-05-08 1998-11-12 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
US6490476B1 (en) * 1999-10-14 2002-12-03 Cti Pet Systems, Inc. Combined PET and X-ray CT tomograph and method for using same
CN100579577C (zh) * 2002-03-15 2010-01-13 退伍军人事务研发服务部 使用细胞脱唾液酸决定簇和糖缀合物将细胞靶向组织和器官的方法和组合物

Also Published As

Publication number Publication date
MXPA05003843A (es) 2006-02-17
EP1554575A2 (en) 2005-07-20
AU2003287091B2 (en) 2010-04-08
AU2003287091A2 (en) 2004-05-04
EA200500625A1 (ru) 2006-06-30
JP2006505554A (ja) 2006-02-16
CN1711475A (zh) 2005-12-21
WO2004033667A3 (en) 2004-10-14
US20060171883A1 (en) 2006-08-03
KR20050062605A (ko) 2005-06-23
CA2501527A1 (en) 2004-04-22
WO2004033667A2 (en) 2004-04-22
AU2003287091A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
Brentville et al. Post-translational modifications such as citrullination are excellent targets for cancer therapy
Johnson et al. Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study
O'Toole et al. Lymphocyte cytotoxicity in bladder cancer no requirement for thymus-derived effector cells?
Garrido et al. H–2-like specificities of foreign haplotypes appearing on a mouse sarcoma after vaccinia virus infection
Caricchio et al. Ultraviolet B radiation-induced cell death: critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution
Gulley et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
Stach et al. Treatment with annexin V increases immunogenicity of apoptotic human T-cells in Balb/c mice
BR0009537A (pt) Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso
Hundemer et al. Identification of a new HLA-A2–restricted T-cell epitope within HM1. 24 as immunotherapy target for multiple myeloma
RU2009122204A (ru) Микроорганизмы и их фракции, индуцирующие специфичный к углеводу клеточный иммунитет
BR112013007064A2 (pt) composições e métodos para a prevenção e tratamento do câncer
Mould et al. Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission
Cappello et al. Next generation immunotherapy for pancreatic cancer: DNA vaccination is seeking new combo partners
WO2000052165A3 (en) Compositions and methods for breast cancer therapy and diagnosis
Guillou et al. Inhibition of leucocyte migration by tumour-associated antigens of the colon and rectum
Rumjanek et al. Schistosoma mansoni: modulation of schistosomular lipid composition by serum
BR0314471A (pt) Detecção, localização e estadiamento de tumores usando linfócitos ativados classificados dirigidos a um epitopo especìfico do tumor
Baldwin et al. Neoantigen expression in chemical carcinogenesis
Moody et al. CD1: from molecules to diseases
Mattijssen et al. Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma
Igarashi et al. Adjuvant activity of synthetic N-acetylmuramyl-L-alanyl-D-isoglutamine and related compounds on cell-mediated cytotoxicity in syngeneic mice
Amanuma et al. Increased infiltration of CD1d+ and natural killer T cells in periodontal disease tissues
Kobayashi et al. Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation
CA3237903A1 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
Merimsky et al. The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.